Clinical trial NCT05128786: CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas
Official title: A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT301-38) in Patients With Relapsed or Refractory AXL Positive Sarcomas
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: SAR
Keywords: AXL, CAR-T, CCT301-38, sarcoma
CAR-T
CCT301-38
sarcoma
Lead sponsor: Shanghai PerHum Therapeutics Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Shanghai Zhongshan Hospital
First posted: 2021-11-22
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This clinical study is to investigate the safety and tolerability of CCT301-38 CAR modified autologous T cells (CCT301-38) in subjects with relapsed or refractory AXL positive sarcomas

Detailed description: This study is an open label, single-center Phase I dose escalation trial to assess the safety, tolerability, DLT and MTD of CCT301-38 cell therapy in patients with AXL positive relapsed or refractory sarcomas.

Subjects that meet inclusion criteria with positive AXL biopsy (IHC 1+ or greater in ≥50% tumor cells) will receive CCT301-38 according to the 3+3 dose escalation design.

Eligibility criteria: Inclusion Criteria:

1. Patients with willingness to be in the study and follow all study procedures, and capable of providing informed consent
2. Male or female aged 18-70 years;
3. Patients with unresectable, locally advanced or metastatic relapse/refractory sarcomas that have failed at least the front line standard treatment confirmed by histology or cytology;
4. At least one measurable lesion, i.e. the length of non-lymph node lesions examined according to CT cross-sectional scanning or magnetic resonance imaging (MRI), or the short diameter of the lymph node lesions is ≥15 mm according to RECIST 1.1, and the FDG PET signal from the measurable lesion is \> 3 SUV;
5. Tumors with AXL positive (IHC 1+ or greater) in ≥50% of all tumor cells. A new biopsy is required if the sample is over one year.
6. ECOG Performance Status 0-1;
7. Expected survival greater than 12 weeks;
8. Adequate organ and hematopoietic system functions to meet the following requirements:

   * Hemoglobin (HGB) s 90 g/L, no blood transfusions within two weeks;
   * White blood cell (WBC) count≥2.5×109/L；
   * Absolute Neutrophil Count (ANC) ≥1.5×109/L;
   * Platelet (PLT) count ≥80×109/L;
   * Total bilirubin (TBIL) ≤3.0ng/dL or ≤5 ULN;
   * ALT and AST ≤5 ULN; for liver metastasis, ALT and AST ≤5 ULN
   * Creatinine (Cr) ≤1.5 x ULN; or creatinine removal rate (CrCl) ≥50 mL/min;
9. PT: INR \< 1.7 or extended PT to normal value \< 4s
10. Normal language, recognition and consciousness assessed by investigator during screening phase;
11. Capable of receiving treatment and follow-up, including treatment in the clinical center;

Exclusion Criteria:

1. Females with pregnancy or in lactation period;
2. Subjects with active hepatitis B, or active hepatitis C. Subjects with undetectable HBV DNA or HCV RNA after anti-virus treatment can be enrolled;
3. HIV positive;
4. Other active infections of clinical significance;
5. Subjects with the following previous or accompanying diseases:

   • Subjects diagnosed as severe autoimmune diseases that require long term (more than 2 months) treatment with systemic immunosuppressants (steroids), or diseases with immune-mediated symptoms, including ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), and autoimmune vasculitis (e.g. Wegena granuloma);
6. Patients with previous diagnosis as motor neuron disease caused by autoimmunity;
7. Patients previously suffered from toxic epidermal necrolysis (TEN)
8. Patients with any mental illness, including dementia, mental changes, which may cause difficulties understanding the informed consent and related questionnaires;
9. Patients with serious uncontrollable diseases, which may interfere with the therapies in this study;
10. Patients with other active malignancies in the past 5 years excluding those with completely cured basal or squamous skin cancers, superficial bladder cancers or primary breast cancers without need of follow-up treatment;
11. Subjects receiving systemic steroids or steroid inhalants;
12. Patients who have received tumor immunotherapy (including monoclonal antibody against PD-1, PD-L1, PD-L2, CD137 or CTLA-4, or cell therapy) in the past 4 weeks;
13. Subjects allergic to immunotherapies or related drugs;
14. Patients with metastatic lesions in meninges or central nervous system, or clear evidence of central nervous system diseases with continuous significant symptoms in the last 6 months;
15. Patients with NYHA class II heart failure, or hypertension incontrollable by standard care, or medical history of myocarditis, or heart attack within a year;
16. Subjects who have received or are going to receive organ transplantation;
17. Patients with active bleeding;
18. Patients with incontrollable pleural or abdominal fluid that needs clinical treatment or intervention;
19. Patients as determined by the investigators to be inappropriate for the study.

Primary outcomes:
measure: DLT
timeFrame: 28 days following infusion
Secondary outcomes:
measure: ORR
timeFrame: Up to 52 weeks
measure: DCR
timeFrame: Up to 52 weeks
measure: DOR
timeFrame: Up to 52 weeks
measure: PFS
timeFrame: Up to 52 weeks
measure: TEAE
timeFrame: Up to 52 weeks
measure: PK
timeFrame: Up to 52 weeks
measure: Biomarker
timeFrame: Up to 52 weeks
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Zhongshan Hospital Affiliated to Fudan University
state: Shanghai
Study officials:
References: